New York Blood Center and Columbia University partner to advance the use of mRNA technology in HIV vaccine study

New York Blood Center’s Project ACHIEVE and Columbia University’s Columbia Research Unit are working in partnership for the New York City effort to advance the use of messenger ribonucleic acid (mRNA) technology in an HIV preventive vaccine study – HVTN 302.

Related Keywords

New York ,United States ,Columbia University ,Hong Van Tieu ,Danielle Ellis ,Magda Sobieszczyk ,National Institute Of Allergy ,National Institutes Of Health ,Drug Administration ,York Blood Center Project ,Vaccine Initiative ,Scripps Research ,Scripps Consortium ,Columbia University Research Unit ,Vaccine Development ,Vaccine Trials Network ,Laboratory Of Infectious Disease Prevention ,Fred Hutchinson Cancer Research Center ,Columbia Research Unit ,New York City ,Trials Network ,National Institute ,Infectious Diseases ,National Institutes ,Infectious Disease Prevention ,New York Blood Center ,Principal Investigator ,Columbia Research ,Blood ,Shiv ,Vaccine ,Kids ,Allergy ,Dancer ,Fell ,Covid 19 ,Na ,Wood ,Immune System ,Muscle ,Research ,Ibonucleic Acid ,Virus ,